Posted by Michael Wonder on 19 Apr 2022
Innovative Cellular Therapeutics receives FDA fast track designation for GCC19CART, its lead solid tumour candidate, in the treatment of patients with relapsed or refractory metastatic colorectal cancer
19 April 2022 - GCC19CART is an autologous CAR T therapy candidate that has shown promising results in over 30 relapsed or refractory metastatic colorectal cancer patients in China.
Innovative Cellular Therapeutics today announced that the U.S. FDA has granted fast track designation to GCC19CART, the Company’s lead solid tumour therapy candidate in treating patients with relapsed and refractory metastatic colorectal cancer
